

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Philippe DIAZ et al.)
Application No.:) Group Art Unit:
Filed: February 20, 2004) Examiner:
For: HETEROCYCLIC BIARYL) Confirmation No.:
COMPOUNDS, PHARMACEUTICAL) 37 C.F.R. § 1.53(b)
AND COSMETIC COMPOSITIONS) Continuation of Appln. No. 09/379,308,
CONTAINING THEM AND USES) Filed August 23, 1999
THEREOF)

FIRST INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

All of the listed documents were previously made of record in prior Application Serial No. 09/379,308, filed August 23, 1999, upon which Applicants rely for the benefits provided in 35 U.S.C. § 120. Therefore, no copies of the listed documents are required to be filed herein.

The documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

FIRST Information Disclosure Statement
Application No.
Attorney's Docket No. 016800-666
Page 2

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned with the next official communication.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date February 20, 2004

By: Mary Katherine Baumeister
Mary Katherine Baumeister
Registration No. 26,254

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Substitute for form 1449A/PTO & 1449B/PTO				<i>Complete if Known</i>	
FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>				Application Number	
Sheet	1	of	3	Filing Date	February 20, 2004
				First Named Inventor	Philippe DIAZ et al.
				Examiner Name	
				Attorney Docket Number	016800-666

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
	3,917,654		Petracek	11-04-1975
	4,704,462		Chang et al.	11-03-1987
	5,696,104		Demarchez et al.	12-09-1997
	5,827,500		Demarchez et al.	10-27-1998
	5,981,776		Diaz et al.	11-09-1999

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation	
					Yes	No
	0 526 951		EP	February 1993		
	0 470 039		EP	July 1991		
	0 322 004		EP	June 1989		
	96/03396		WO	February 1996		

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	<i>Chemical Abstracts</i> , Vol. 113, p. 706, 1990, Chemical Abstracts Service, Columbus, OH
	Strickland et al., <i>Cancer Research</i> 43, 5268, November, 1983, American Association for Cancer Research, Baltimore, MD
	Verma, A.K. et al., <i>Cancer Research</i> 38, 793-801, March 1978, American Association for Cancer Research, Baltimore, MD
	<i>Chem Abstr</i> , 115: 8229 v, 1991, Chemical Abstracts Service, Columbus, OH
	Bailly et al, <i>Skin Pharmacol</i> . 3, 256-267, 1990, S. Karger AG, Basel Switzerland.
	Levin et al, <i>Nature</i> , Vol. 355, 359-361, 1992, Macmillan Magazines Ltd, London, England.
	Allenby et al, <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 90, 30-34, 1993, The National Academy of Sciences, Washington, D.C.
	<i>Fitzpatrick's Dermatology in General Medicine</i> , fifth edition, eds., Freedberg et al, Volume 1, pp. 509-510, 769, 2798, 2801, 2810-2811, 1999, McGraw-Hill, New York.
	Jomard et al, poster presented at Congres Annuel de Recherche en Dermatologie, April 10-11, 1997, Tours, France.
	Abstract (only) of Brattsand, <i>Atherosclerosis</i> , 22, 47-61, Jul-Aug 1975
	Abstract (only) of Butturini, <i>Acta Vitaminol Enzymol</i> , 4, 15-9, 1982
	Abstract (only) of Bikle et al, <i>J Invest Dermatol</i> , 101, 713-8, 1993

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FIRST
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	of	3	Attorney Docket Number	016800-666
-------	---	----	---	------------------------	------------

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Abstract (only) of Humphrey et al, <i>J. Nutr.</i> , 123, 1363-9, Aug 1993
	Abstract (only) of Louthrenoo, <i>J. Rheumatol.</i> , 20, 1243-6, Jul 1993
	Abstract (only) of Berson et al, <i>Arch Ophthalmol.</i> , 111, 761-72, Jun 1993
	Abstract (only) of Bollag et al, <i>J Cell Physiol.</i> , 163, 248-56, 1995
	Abstract (only) of Morkeberg et al, <i>Graefes Arch Clin Exp Ophthalmol.</i> , 233, 709-13, Nov. 1995
	Abstract (only) of Jacobson et al, <i>Nat Genet.</i> , 11, 27-32, Sep 1995
	Abstract (only) of Fekrat et al, <i>Ophthalmology</i> , 102, pp. 412-8, Mar 1995
	Abstract (only) of Boehm et al., <i>Chem Biol.</i> , 6, 265-75, 1999
	Abstract (only) of Christakos et al, <i>Biochem J.</i> , 316, 361-71, Jun 1996
	Abstract (only) of Murphy et al, <i>Bone Marrow Transplant.</i> , 18, 641-2, Sep 1996
	Abstract (only) of James et al, <i>Leukemia</i> , 11, 1017-25, Jul 1997
	Abstract (only) of Takahashi et al, <i>Curr Eye Res.</i> , 16, 703-9, Jul 1997
	Abstract (only) of Del Prete et al, <i>Ophthalmologica</i> , 211, 101-3, 1997
	Abstract (only) of Brown, <i>Am J Kidney Dis.</i> , 32, S25-39, Oct 1998
	Abstract (only) of Sibulesky, <i>Am J Clin Nutr.</i> , 69, 656-63, Apr 1999
	Abstract (only) of Blanche, <i>Clin Exp Rheumatol.</i> , 17(1), pp. 105-6, Jan-Feb 1999
	Abstract (only) of Swamidas et al, <i>J Nutr.</i> , 129(7), pp. 1285-90, Jul 1999
	Abstract (only) of Lenhard et al., <i>Diabetologia</i> , 42(5), pp. 545-54, May 1999
	Abstract (only) of Vuligonda et al, <i>Bioorg Med Chem Lett.</i> , 9(4), pp. 589-94, Feb 1999
	Abstract (only) of Canan et al, <i>J Med Chem.</i> , 42(4), pp. 742-50, Feb 25 1999
	Abstract (only) of Chen et al, <i>Clin Cancer Res.</i> , 6(3), pp. 901-8, Mar 2000
	Abstract (only) of Wiegman et al, <i>Arterioscler Thromb Vasc Biol.</i> , 20(1), pp. 89-95, Jan 2000
	Abstract (only) of Nagpal et al, <i>Curr Pharm Des.</i> , 6(9), pp. 919-931, June 2000
	Abstract (only) of Mu et al, <i>Biochem Biophys Res Commun.</i> , 271(3), pp. 710-3, May 2000

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FIRST
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	3	of	3	Attorney Docket Number	016800-666
-------	---	----	---	------------------------	------------

Complete if Known

Application Number	
Filing Date	February 20, 2004
First Named Inventor	Philippe DIAZ et al.
Examiner Name	

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Abstract (only) of Thacher et al, <i>Curr Pharm Des</i> , 6(1), pp. 25-58, Jan 2000
	Benedetti, <i>Blood</i> 87(5), 1939-50, 1996, American Society of Hematology, Washington, D.C.
	Byers S, <i>Endocrinology</i> 137(8), 3265-73, 1996, Endocrine Society, Baltimore, MD
	Chandraratna RA, <i>Journal of the American Academy of Dermatology</i> 37 (2 Pt 3), S12-S17, 1997, Mosby, St. Louis, MO
	Chen S et al, <i>Journal of Pharmacy and Pharmacology</i> 47(8), 626-31, 1995, Pharmaceutical Society of Gt. Britain, London, England
	Dockx P., <i>British Journal of Dermatology</i> 133(3), 426-32, 1995, Blackwell Scientific Publications, Oxford, England
	Elder J T et al., <i>Journal of Investigative Dermatology</i> 106(3), 517-21, 1996, Blackwell Science, Malden, MA
	Kinoshita et al., <i>Blood</i> , 95(9), 2821-8, 2000, American Society of Hematology, Washington, D.C.
	Miller W. H. et al., <i>Blood</i> 85(11), 3021-7, 1995, American Society of Hematology, Washington, D.C.
	Muccio D. et al., <i>J. Med Chem.</i> 41 (10), 1679-87, 1998, American Chemical Society, Washington, D.C.
	Paraskevaidis A et al., <i>Dermatology</i> 196(1), 171-5, 1998, Karger, Basel, Switzerland
	Sakae et al., <i>Molecular Pharmacology</i> 55(4), 668-76, 1999, American Society for Pharmacology and Experimental Therapeutics, Bethesda, MD
	Shiohara M et al., <i>Blood</i> 93(6), 2057-66, 1999, American Society for Hematology, Washington, D.C.
	Sun S Y et al., <i>Cancer Research</i> 57(21), 4931-9, 1997, American Association for Cancer Research, Baltimore, MD
	Tashima T et al, <i>Chemical and Pharmaceutical Bulletin</i> 45(11), 1805-13, 1997, Pharmaceutical Society of Japan, Tokyo, Japan
	Tockman, <i>IARC Scientific Publications</i> 154, 257-70, 2001
	Wan H et al., <i>Cancer Research</i> , 61(2), 556-64, 2001, American Association for Cancer Research, Baltimore, MD
	Weinstein G. D., et al. <i>Journal of the American Academy of Dermatology</i> 37(1), 85-92, 1997, Mosby, St. Louis, MO

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.